Mencevax ACWY (Smith KIine Beecham)
monodose and multidose vials containing lyophilised vaccine for reconstitution
Indication: meningitis prophylaxis
Meningococci are divided into serologic groups by the different antigens in their capsular polysaccharides. Serious disease is caused by groups A, B, C, W and Y. The previously available vaccine contained purified polysaccharides from groups A and C only.
The reformulated vaccine is approved for use in controlling epidemics or immunising the contacts of patients infected with A, C, W 135 or Y meningococci. Travellers to countries where the disease is endemic or highly epidemic can also be immunised.
Little data are available on the use of the vaccine in children under 14 years of age and there are no data on the protective efficacy of the antibody response to the added W 135 and Y polysaccharides. The vaccine offers no protection against infection by other groups.
Local reactions to the vaccine occur in a majority of patients and may be more frequent in children.